Clinical Trials Directory

Trials / Completed

CompletedNCT02362087

Taxane Acute Pain Syndrome (TAPS) in Patients Receiving Taxane Chemotherapy for Breast or Prostate Cancer

A Multi-Centre Study to Investigate the Natural History of Taxane Acute Pain Syndrome (TAPS) in Patients Receiving Taxane Chemotherapy for Breast or Prostate Cancer

Status
Completed
Phase
Study type
Observational
Enrollment
75 (actual)
Sponsor
Ottawa Hospital Research Institute · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to document what course of action physicians choose for their patients when they develop taxane acute pain syndrome (TAPS) and to identify patients at the greatest risk of TAPS by examining specific human genome markers such as single nucleotide polymorphisms (SNPs) and Copy Number Variations (CNVs) that may explain the genetic (hereditary) component.

Conditions

Interventions

TypeNameDescription
OTHERQuality of life and brief pain inventoryblood collection and quality of life questionnaires and a pain medication diary

Timeline

Start date
2015-03-01
Primary completion
2016-07-01
Completion
2016-07-01
First posted
2015-02-12
Last updated
2019-09-06

Locations

1 site across 1 country: Canada

Source: ClinicalTrials.gov record NCT02362087. Inclusion in this directory is not an endorsement.

Taxane Acute Pain Syndrome (TAPS) in Patients Receiving Taxane Chemotherapy for Breast or Prostate Cancer (NCT02362087) · Clinical Trials Directory